The clinical trial enrolled both patients with RET-mutant MTC (n = 122) who were treatment naive or had previously received cabozantinib or vandetanib, or both, as well as patients with RET-fusion positive TC (n = 20) (RR of 71%, 60%, and 89%, respectively) (54). Here, RET is linked to medullary thyroid gland carcinoma.